secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001213900-24-012571
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phoenix Biotech shareholders approve business combination with CERo Therapeutics
--------------------------------------------------------------------------------

- All 8 proposals passed with over 99% of voted shares in favor at Feb 8 special meeting.
- 5,493,678 shares voted for the Business Combination Agreement; 10,588 abstained, none against.
- Holders of 671,285 Class A common shares exercised redemption rights for ~$7.46M ($11.11/share).
- New company to be named CERo Therapeutics Holdings Inc. post-merger.
- Five directors appointed for New CERo: Byrnes, Atwood, LaPorte, Corey, Ehrlich.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/0001213900-24-012571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024012571/ea193300-8k425_phoenix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-012571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer